Preferred Label : Ticagrelor;
NCIt synonyms : (1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol;
NCIt definition : An orally bioavailable cyclopentyltriazolopyrimidine, with antiplatelet activity.
Upon oral administration, ticagrelor and its major metabolite targets and reversibly
binds to the platelet adenosine diphosphate (ADP) P2Y12 receptor (P2Y12R) at a site
distinct from that of the endogenous agonist ADP. This blocks the platelet signaling
pathway, thereby inhibiting the activation of the glycoprotein complex GPIIb/IIIa,
fibrinogen binding to platelets and platelet adhesion and aggregation.;
UNII : GLH0314RVC;
InChIKey : OEKWJQXRCDYSHL-FNOIDJSQSA-N;
CAS number : 274693-27-5;
Drug name : Brilinta; Thioxlant-6C; Brilique; Ticalog;
Molecule name : AR-C126532XX; AZD6140;
Chemical formula : C23H28F2N6O4S;
Codes from synonyms : 492;
Origin ID : C76404;
UMLS CUI : C1999375;
Automatic exact mappings (from CISMeF team)
CISMeF manual mappings
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
concept_is_in_subset
https://www.usherbrooke.ca/baladocritique/archives/episode-63-etude-ultimate-dapt
2024
France
sound
Off Study
On Study
singular
double
Dual Anti-Platelet Therapy
therapy, nos
high pitch
Ticagrelor
data collection
Papaverine Hydrochloride
Ticagrelor
Double
acute coronary syndrome
Episode
Acute Coronary Syndrome
Clinical Study
ticagrelor
episode of
ultimatism
DICOM Study
---